Harrow targets $250M quarterly revenue by 2027; Leerink sets $45
Harrow outlined a five-year roadmap targeting $250M quarterly revenue by 2027, while Leerink Partners initiated coverage with an Outperform rating and a $45 price target.
Harrow, Inc. (NASDAQ:HROW) laid out a five-year roadmap targeting $250M in quarterly revenue by 2027, with growth expected to come from products such as G-MELT, IHEEZO and VEVYE, as well as new launches, acquisitions and clinical data. Leerink Partners initiated coverage on the stock with an Outperform rating and a $45 price target.